WINDFALL FILMS LIMITED

Financial Health Assessment: WINDFALL FILMS LIMITED

1. Financial Health Score: D The patient is experiencing acute financial distress. While the heart is still beating—evidenced by growing revenues and a positive cash balance—the business is bleeding heavily from operational losses. The severe drop in equity and reliance on high-cost, short-term financing are classic symptoms of a business struggling to maintain a healthy circulatory system. Immediate intervention is required to stop the hemorrhaging and stabilize the condition.

2. Key Vital Signs * Revenue (Heart Rate): £12.36M (Up 6.5%) — The patient's heart rate is strong and steady. Revenue has recovered from the previous year, indicating that the core business is still winning contracts and generating demand for its content. * Operating Loss (Blood Pressure): £1.18M Loss — Dangerously high pressure. After a minor loss of £39k in 2023, the business suffered a severe operating loss of £1.18M in 2024. This indicates that the cost of delivering on contracts is vastly outpacing the income generated. * Net Assets & Equity (Cholesterol/Weight): £417k (Down 74%) — A dangerous narrowing of the arteries. Net assets plummeted from £1.6M to just £417k. The business is heavily leveraged, with total liabilities (£9.73M) towering over total assets (£11.16M). The debt-to-equity ratio is dangerously high at approximately 23:1. * Cash Reserves (Oxygen Levels): £951k (Up from £311k) — Superficially, oxygen levels look healthy. However, this cash appears to be artificially inflated by an increase in debt rather than operational breath (profit). The subsequent post-balance-sheet high-interest loans suggest the patient is relying on an oxygen tank to keep breathing.

3. Diagnosis Windfall Films is suffering from Acute Margin Compression and Operational Hemorrhaging.

While the company's top-line revenue is healthy, its gross profit contracted from £4.17M to £4.07M despite generating £750k more in turnover. This means the cost of sales is rising at a much faster rate than revenue—a clear symptom that the business is failing to control production costs or is accepting unprofitable work.

The £1.18M operating loss has severely eroded the company's retained earnings and equity base, leaving it financially fragile. The balance sheet shows a heavy reliance on creditors and debt to fund operations. Most alarmingly, the post-balance-sheet events reveal that the company has recently entered into joint production loan agreements with interest rates ranging from 1.10% to 2.00% per month (equivalent to roughly 13% to 24% annually). Turning to high-cost, short-term financing is a classic symptom of cash flow anemia and distress. The auditors have signed off on the going concern basis, but the patient is on life support.

4. Recommendations * Triage Production Costs (Stop the Bleeding): The execution risk mentioned in the strategic report has materialized. Management must urgently audit production budgets to identify where overspends are occurring. Fixed budgets must be strictly enforced, and unprofitable projects must be re-evaluated or culled. * Refinance High-Cost Debt (Clear the Arteries): The recent high-interest production loans are toxic. The company must explore restructuring this debt through more traditional, lower-cost financing avenues before the compounding interest becomes terminal. * Focus on Gross Margin Health (Build Immunity): Revenue growth is meaningless if it does not contribute to gross profit. The leadership team must prioritize margin over volume, focusing on contracts that yield a healthier gross profit to rebuild the equity buffer. * Strengthen Working Capital (Pulse Check): With net assets at just £417k against nearly £10M in liabilities, there is no room for error. Directors must aggressively chase debtor payments and negotiate longer terms with creditors to improve working capital without relying on expensive bridging finance.